Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Practical management of PARP inhibitors: A French DELPHI consensus].
Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A. Selle F, et al. Among authors: berton d. Bull Cancer. 2022 Dec;109(12):1245-1261. doi: 10.1016/j.bulcan.2022.06.011. Epub 2022 Sep 13. Bull Cancer. 2022. PMID: 36109248 Free article. French.
The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
Lenck C, Chopin N, Gouy S, Bonsang-Kitzis H, Martinez-Gomez C, Radosevic-Robin N, Martin S, Lefeuvre-Plesse C, Lambaudie E, Leblanc E, Guyon F, Classe JM, Ramanah R, Beurrier F, Angeles MA, Pomel C, Joly F, de la Motte Rouge T, Provansal M, Lesoin A, Floquet A, Berton D, Kalbacher E, Chakiba C, Meeus P, Selle F, Treilleux I, Lecuru F, Pautier P, Ray-Coquard I. Lenck C, et al. Among authors: berton d. Gynecol Oncol. 2020 Apr;157(1):78-84. doi: 10.1016/j.ygyno.2020.02.012. Epub 2020 Mar 2. Gynecol Oncol. 2020. PMID: 32131977
GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F, Heudel PE, Hardy-Bessard AC, Pozet A, Meunier J, Gladieff L, Lotz JP, Provansal M, Augereau P, Berton D, Bonichon-Lamichhane N, Orfeuvre H, Pautier P, Kalbacher E, Tazi Y, Spaeth D. Selle F, et al. Among authors: berton d. Anticancer Res. 2020 Jul;40(7):3939-3945. doi: 10.21873/anticanres.14385. Anticancer Res. 2020. PMID: 32620635
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Blanc-Durand F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux É, Berton D, Bello-Roufai D, Guillemet C, Dupre PF, Faller É, Alexandre J, Hardy-Bressard AC, Collard O, Fabbro M, Provansal M, Kalbacher E, Genestie C, Pautier P. Blanc-Durand F, et al. Among authors: berton d. Gynecol Oncol. 2020 Oct;159(1):129-135. doi: 10.1016/j.ygyno.2020.07.019. Epub 2020 Jul 25. Gynecol Oncol. 2020. PMID: 32723678
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, Berton D, Leary A, Moore KN, Estevez-Diz MDP, Hardy-Bessard AC, Alexandre J, Opperman CP, de Azevedo CRAS, Randall LM, Feliu WO, Ancukiewicz M, Ray-Coquard I. O'Malley DM, et al. Among authors: berton d. Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25. Gynecol Oncol. 2021. PMID: 34452745 Free article. Clinical Trial.
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients.
Berton D, Floquet A, Lescaut W, Baron G, Kaminsky MC, Toussaint P, Largillier R, Savoye AM, Alexandre J, Delbaldo C, Malaurie E, Barletta H, Bosacki C, Garnier-Tixidre C, Follana P, Laharie-Mineur H, Briac Levache C, Valenza B, Dechartres A, Mollon-Grange D, Selle F. Berton D, et al. Front Pharmacol. 2021 Sep 20;12:711813. doi: 10.3389/fphar.2021.711813. eCollection 2021. Front Pharmacol. 2021. PMID: 34616296 Free PMC article.
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, Floquet A, Vegas H, Bourgeois H, Bengrine Lefevre L, You B, Pommeret F, Lortholary A, Spaeth D, Hardy-Bessard AC, Abdeddaim C, Kaminsky-Forrett MC, Tod M, Kurtz JE, Del Piano F, Meunier J, Raban N, Alexandre J, Mouret-Reynier MA, Ray-Coquard I, Provansal Gross M, Brachet PE. Joly F, et al. Among authors: berton d. Gynecol Oncol. 2022 Sep;166(3):389-396. doi: 10.1016/j.ygyno.2022.06.022. Epub 2022 Jul 26. Gynecol Oncol. 2022. PMID: 35902297 Clinical Trial.
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M. Bellier C, et al. Among authors: berton d. Drugs Real World Outcomes. 2023 Jun;10(2):207-213. doi: 10.1007/s40801-022-00349-9. Epub 2023 Jan 11. Drugs Real World Outcomes. 2023. PMID: 36630055 Free PMC article.
Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
Bourien H, Lefevre LB, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Gavoille L, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Tixidre CG, Coeffic D, Morvan A, Collard O, DE LA Motte Rouge T. Bourien H, et al. Among authors: berton d. Anticancer Res. 2023 Feb;43(2):653-662. doi: 10.21873/anticanres.16202. Anticancer Res. 2023. PMID: 36697069
147 results